BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38338651)

  • 1. Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer.
    Huang HN; Hung PF; Chen YP; Lee CH
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.
    Shuai S; Liao X; Wang H; Liu L; Mei S; Cao J; Wang S
    Cancer Sci; 2021 Oct; 112(10):4139-4150. PubMed ID: 34058054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
    Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
    Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells.
    Fujiwara R; Taniguchi Y; Rai S; Iwata Y; Fujii A; Fujimoto K; Kumode T; Serizawa K; Morita Y; Espinoza JL; Tanaka H; Hanamoto H; Matsumura I
    Biochem Biophys Res Commun; 2022 Oct; 626():156-166. PubMed ID: 35994825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
    Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
    Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
    Minakata K; Takahashi F; Nara T; Hashimoto M; Tajima K; Murakami A; Nurwidya F; Yae S; Koizumi F; Moriyama H; Seyama K; Nishio K; Takahashi K
    Cancer Sci; 2012 Nov; 103(11):1946-54. PubMed ID: 22863020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
    Kook E; Lee J; Kim DH
    Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC.
    Chen Y; Zhang C; Jin S; Li J; Dai J; Zhang Z; Guo R
    J Cell Mol Med; 2023 Jul; 27(14):2032-2044. PubMed ID: 37278440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
    Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H
    BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
    Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
    Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.
    Frezzetti D; Caridi V; Marra L; Camerlingo R; D'Alessio A; Russo F; Dotolo S; Rachiglio AM; Esposito Abate R; Gallo M; Maiello MR; Morabito A; Normanno N; De Luca A
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
    J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation.
    Ma C; Zhang X; Mo X; Yu Y; Xiao Z; Wu J; Ding L; Lei C; Zhu Y; Zhang H
    Phytomedicine; 2024 Mar; 125():155351. PubMed ID: 38232540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
    Liu D; Cao Z; Xu W; Lin G; Zhou X; Ding X; Wang N; Wu C; Su B
    Biomed Pharmacother; 2019 Sep; 117():109185. PubMed ID: 31387179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
    Tian Y; Zhang Z; Miao L; Yang Z; Yang J; Wang Y; Qian D; Cai H; Wang Y
    Oncol Res; 2016; 24(5):295-303. PubMed ID: 27712586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.
    Togashi Y; Hayashi H; Nakagawa K; Nishio K
    Drug Des Devel Ther; 2014; 8():1037-46. PubMed ID: 25114510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.